Events

.. Read More →

AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference 2019 – Poster Antitumor activity of STRO-002, a novel anti-folate receptor -⍺ (FolR⍺) antibody drug conjugate (ADC), in.. Read More →

Sutro Biopharma Presents Encouraging Preliminary Clinical Data in Ongoing Phase I Study for STRO-002 Antibody-Drug Conjugate in Patients with Advanced Ovarian Cancer – Data is.. Read More →

Antitumor activity of STRO-002, a novel anti-folate receptor-α (FRα) antibody drug conjugate (ADC), in patient-derived xenograft (PDX) models and preliminary Phase I dose escalation safety.. Read More →

SOUTH SAN FRANCISCO, Calif., Oct. 16, 2019 – Sutro Biopharma, Inc. (NASDAQ: STRO) today announced that the company will present at the upcoming AACR-NCI-EORTC International.. Read More →

World Anti-Body Drug Conjugate (ADC) 2019  Process Development and Scale Up for Site-Specific Bioconjugate Conjugation and Purification Please Click the Link, World ADC 2019 Poster to.. Read More →

SOUTH SAN FRANCISCO, Calif., Sept. 4, 2019 – Sutro Biopharma, Inc. (NASDAQ: STRO) today announced that Bill Newell, CEO of Sutro Biopharma, will present a.. Read More →

SOUTH SAN FRANCISCO, Calif., Aug. 8, 2019 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application.. Read More →

SOUTH SAN FRANCISCO, Calif., June 18, 2019 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application.. Read More →

SOUTH SAN FRANCISCO, Calif., May 16, 2019 – Sutro Biopharma, Inc. (NASDAQ: STRO) today announced that the company will present at the upcoming European Hematology.. Read More →

SOUTH SAN FRANCISCO, Calif., March 5, 2019 –Sutro Biopharma, Inc. (NASDAQ: STRO) today announced that Bill Newell, Chief Executive Officer, will present at the Cowen.. Read More →

SOUTH SAN FRANCISCO, Calif., Jan. 3, 2019 –Sutro Biopharma, Inc. (NASDAQ: STRO) today announced that Bill Newell, Chief Executive Officer, will present at the 37th.. Read More →

SOUTH SAN FRANCISCO, Calif., Nov. 26, 2018  — Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application.. Read More →

https://invivo.pharmamedtechbi.com/IV005100/Cancers-NextGen-Smart-Bomb-Who-Will-Be-First-To-Weaponize    .. Read More →

Modern biotechnology is a young industry. But in just a few decades, the entrepreneurs, scientists, researchers and investors working in this field have firmly established themselves.. Read More →

NPR and BioTech Nation interview Sutro’s CEO William Newell to learn more about the next generation of cancer therapeutics. Click here to listen to the.. Read More →

SAN FRANCISCO, Nov. 18, 2015 /PRNewswire/ — Sutro Biopharma today announced that it was awarded the Outstanding Partner Award, at the California Life Sciences Association.. Read More →

  San Francisco, CA – September 22, 2014 – Sutro Biopharma today announced that it has been named by FierceBiotech as one of 2014’s Fierce.. Read More →

On July 1, 2014, World ADC announced the nominees for the World ADC Awards, 2014. Sutro Biopharma’s cell free expression system, Xpress CF+™, has made.. Read More →

Press release published by EnWave Corporation regarding the recent agreement with Sutro Biopharma, Inc. Read more.. Read More →

Scientific American Guest Blog Antibody-Drug Conjugates and Cancer Treatment: Making “Smart Bombs” Smarter By: Trevor J. Hallam Read More.. Read More →

12/5/2011 – BioPharm International Podcast (3of3): Sutro Biopharma’s Trevor Hallam offers a glimpse into the future of drug design By: Trevor J. Hallam.. Read More →

BioPharm International Podcast (2of3): Sutro Biopharma’s Trevor Hallam describes a future cGMP manufacturing facility By: Trevor J. Hallam.. Read More →

BioPharm International Podcast (1of3): Sutro Biopharma and Cell-Free Protein Expression Systems By: Trevor J. Hallam.. Read More →

PHARMACEUTICAL TECHNOLOGY Volume 35, pp. s8-s11 Industrializing Design, Development, and Manufacturing of Therapeutic Proteins By: Trevor J. Hallam, Christopher J. Murray... Read More →

BioCentury, The Bernstein Report on BioBusiness January 10, 2011 issue article, “Unnatural Selection” in the Tools & Techniques section by BioCentury Senior Editor, Ms. Susan.. Read More →

National Science Foundation (NSF) newsletter featuring Sutro Biopharma and Promising Protein Synthesis Technology. Read More.. Read More →